Inquiry Basket
Loading ......
Filter By Product Search for
ALK
ALK Full Name
anaplastic lymphoma receptor tyrosine kinase
ALK Introduction
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that plays a critical role in cellular growth, differentiation, and survival. Normally expressed during embryonic development in the nervous system, ALK remains largely inactive in adult tissues. However, aberrant activation of ALK through gene rearrangements, point mutations, or amplifications can drive oncogenesis, making it a key therapeutic target in oncology. ALK signaling influences multiple downstream pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT, which collectively regulate cell proliferation, apoptosis resistance, and metastatic potential. Understanding ALK biology has become increasingly important as targeted therapies have reshaped the treatment landscape for ALK-driven cancers.
Clinically, ALK alterations are most notably associated with non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL). In NSCLC, ALK fusion-positive tumors respond dramatically to ALK inhibitors, with second-generation drugs like Alectinib and Brigatinib demonstrating improved overall response rates and progression-free survival compared to first-generation Crizotinib, particularly in controlling brain metastases. Similarly, in pediatric and adult ALK-positive ALCL, targeted inhibition has significantly enhanced long-term survival outcomes, underscoring the importance of precise ALK status testing for treatment stratification. Nevertheless, the emergence of resistance mutations remains a clinical challenge, driving ongoing research into novel inhibitors and combination strategies.
Beyond these common malignancies, ALK alterations have been identified in rare posterior cranial fossa tumors, such as medulloblastomas and astrocytomas. Although the overall mutation frequency is low, their presence may offer diagnostic and therapeutic value, particularly with the development of third-generation ALK inhibitors like Lorlatinib that better penetrate the central nervous system. Complementing clinical advances, computational approaches including molecular docking and ADMET modeling are being employed to design new ALK inhibitors with improved efficacy and pharmacokinetic profiles. These integrated strategies highlight the evolving potential of ALK-targeted therapy to overcome resistance and expand treatment options for both common and rare ALK-driven cancers.
Alternate Names for ALK
ALK; anaplastic lymphoma receptor tyrosine kinase; CD246; NBLST3; ALK tyrosine kinase receptor; CD246 antigen; mutant anaplastic lymphoma kinase;
Loading ......
